期刊文献+
共找到271篇文章
< 1 2 14 >
每页显示 20 50 100
Tyrosine kinase inhibitors and human epidermal growth factor receptor-2 positive breast cancer
1
作者 Aya Abunada Zaid Sirhan +1 位作者 Anita Thyagarajan Ravi P Sahu 《World Journal of Clinical Oncology》 CAS 2023年第5期198-202,共5页
The body of evidence investigating human epidermal growth factor receptor-2(HER2)directed therapy in patients with breast cancer(BC)has been growing within the last decade.Recently,the use of tyrosine kinase inhibitor... The body of evidence investigating human epidermal growth factor receptor-2(HER2)directed therapy in patients with breast cancer(BC)has been growing within the last decade.Recently,the use of tyrosine kinase inhibitors(TKIs)has been of particular interest in the treatment of human malignancies.This literature commentary is intended to highlight the most recent findings associated with the widely-studied TKI agents and their clinical significance in improving the outcomes of HER2 positive BC. 展开更多
关键词 Human epidermal growth factor receptor-2 positive breast cancer Tyrosine kinase inhibitors LAPATINIB Pyrotinib Tucatinib TRASTUZUMAB
下载PDF
Impressive Objective Response to Nab-Paclitaxel plus Trastuzumab as Fifth Line Therapy in an Elderly HER-2 Positive Breast Cancer Patient
2
作者 Maria Rosaria Valerio Chiara Ancona +1 位作者 Antonella Marchese Vittorio Gebbia 《Journal of Cancer Therapy》 2017年第11期933-940,共8页
Background: Agent targeting HER-2 pathway plus chemotherapy has represented a major progress in the management of patients with breast cancer. However, the role of late-line treatment in heavily pretreated patients is... Background: Agent targeting HER-2 pathway plus chemotherapy has represented a major progress in the management of patients with breast cancer. However, the role of late-line treatment in heavily pretreated patients is still largely unclear. In the last decade, nab-paclitaxel has shown significant activity and good toxicity profile in metastatic breast cancer. Case Presentation: We report the case of a 76-year-old Caucasian woman with metastatic HER-2 positive ductal infiltrating breast carcinoma treated with a combination of weekly nab-paclitaxel and trastuzumab as fifth-line therapy. She had previously received first-line paclitaxel and trastuzumab, second-line vinorelbine and trastuzumab, third-line TDM1 and fourth-line oral capecitabine and lapatinib. Clinical and radiological staging showed progression at bone, skin and soft-tissue. The patient received weekly nab-paclitaxel plus trastuzumab. Massive objective response was clinically and PET documented which lasted 8 months. Tolerance to treatment was fairly good as well as cardiac safety. Conclusion: To the best of our knowledge, this is the first reported case of efficacy of nab-paclitaxel in combination with trastuzumab as fifth-line of treatment in a patient with metastatic HER-2 positive breast cancer. 展开更多
关键词 NAB-PACLITAXEL TRASTUZUMAB her-2 Metastasis breast cancer
下载PDF
Current status of PI3K-mTOR inhibition in hormone-receptor positive, HER2-negative breast cancer
3
作者 Navid Sobhani Daniele Generali +2 位作者 Fabrizio Zanconati Marina Bortul Bruna Scaggiante 《World Journal of Clinical Oncology》 CAS 2018年第8期172-179,共8页
Breast cancer (BC) is the most common cancer in women and second only to lung cancer in terms of mortality. Among the three different BC subtypes, the oestrogen receptor positive represents nearly 70% of all cases and... Breast cancer (BC) is the most common cancer in women and second only to lung cancer in terms of mortality. Among the three different BC subtypes, the oestrogen receptor positive represents nearly 70% of all cases and it is usually treated with anti-oestrogen drugs. However, the majority of hormone receptor positive metastatic BC patients develop resistance to anti-oestrogen treatments.The need for more down-stream therapies brought to the development of therapeutic strategies inhibiting the phosphatidylinositol 3-kinase-mammalian target of rapamycin (mTOR) pathway. Inhibitors of the mTOR have been tested in different clinical trials; everolimus has been Food and Drug Administration approved for the treatment of oestrogen receptor positive/human epidermal growth factor receptor 2 negative BC patients in combination with exemestane in patients who have progressed to anastrozole or letrozole after the encouraging results coming from BOLERO-2 trial. Similar results were obtained by the TAMRAD investigatory study testing tamoxifen in combination with everolimus in advanced BC. This editorial focuses on the results from BOLERO-2, BOLERO 4 and BOLERO-6, which tested the clinical importance of mTOR inhibition. We comment also on the role of phosphatidylinositol 3-kinase-mTOR inhibition as reported in the BELLE-2 and BELLE-3 trials and the future directions for the inhibition of this tumour metabolic axis. 展开更多
关键词 HORMONE receptor positive/Her2-negative breast cancer PI3K mTOR TORC1/2 Akt EVEROLIMUS
下载PDF
曲妥珠单抗新辅助化疗治疗HER-2阳性乳腺癌中体重指数与病理完全缓解的关系
4
作者 谢炉峰 缪继东 +2 位作者 蒋朝阳 李家伟 冯江 《河北医药》 CAS 2024年第15期2286-2290,共5页
目的 分析体重指数(BMI)与人表皮生长因子受体2(HER-2)阳性乳腺癌曲妥珠单抗新辅助化疗病理完全缓解(pCR)的关系。方法 收集2018年5月至2022年6月曲妥珠单抗新辅助治疗HER-2阳性乳腺癌患者136例临床资料,分析不同BMI的HER-2阳性乳腺癌... 目的 分析体重指数(BMI)与人表皮生长因子受体2(HER-2)阳性乳腺癌曲妥珠单抗新辅助化疗病理完全缓解(pCR)的关系。方法 收集2018年5月至2022年6月曲妥珠单抗新辅助治疗HER-2阳性乳腺癌患者136例临床资料,分析不同BMI的HER-2阳性乳腺癌临床病理特征,采用单因素及多因素Logistic分析BMI与pCR的关系。结果 136例HER-2阳性乳腺癌患者中,获得pCR 43例(31.62%)。BMI≥24组T分期(Ⅲ~Ⅳ期)、孕激素受体(PR)(阳性)、细胞核增殖抗原(Ki-67)(≥14)、淋巴结转移(阳性)高于BMI<24组(P<0.05)。pCR组与非pCR组年龄、月经状态、Ki-67比较(P>0.05);pCR组T分期(Ⅲ~Ⅳ期)、ER(阴性)、PR(阴性)、淋巴结转移(阳性)、BMI(≥24)低于非pCR组(P<0.05)。孕激素受体(PR)、淋巴结转移、BMI是影响ER-2阳性乳腺癌pCR的危险因素(P<0.05)。结论 曲妥珠单抗新辅助化疗治疗HER-2阳性乳腺癌pCR与PR、淋巴结转移、BMI明显相关,结合BMI与HER-2阳性乳腺癌临床病理特征的关系,BMI是HER-2阳性乳腺癌曲妥珠单抗新辅助化疗pCR的独立危险因素。 展开更多
关键词 her-2阳性乳腺癌 曲妥珠单抗 新辅助化疗 体重指数 病理完全缓解
下载PDF
乳腺超声造影预测HER-2阳性乳腺癌曲妥珠单抗化疗敏感性的价值
5
作者 袁莹莹 蔡艳 +1 位作者 周晓霞 郑国连 《海南医学》 CAS 2024年第18期2676-2679,共4页
目的研究乳腺超声造影预测人类表皮生长因子受体2(HER-2)阳性乳腺癌患者对曲妥珠单抗化疗敏感性的价值。方法回顾性分析2023月1月至2024年1月湛江中心人民医院诊疗的187例HER-2阳性乳腺癌患者的临床和影像资料,所有患者均接受曲妥珠单... 目的研究乳腺超声造影预测人类表皮生长因子受体2(HER-2)阳性乳腺癌患者对曲妥珠单抗化疗敏感性的价值。方法回顾性分析2023月1月至2024年1月湛江中心人民医院诊疗的187例HER-2阳性乳腺癌患者的临床和影像资料,所有患者均接受曲妥珠单抗治疗,按照治疗第1个周期(3周)的疗效分为不敏感组122例和敏感组65例,所有患者在治疗第1个周期结束后均接受乳腺超声造影检查,比较两组患者治疗第1个周期结束后的乳腺超声造影表现。结果治疗敏感组患者病灶的最大径为(2.91±0.33)cm,明显小于不敏感组患者的(4.67±0.75)cm,差异有统计学意义(P<0.05);治疗不敏感组患者的高增强率、快进增强模式、增强后肿物不清晰、增强后肿块形态不规则、周围有穿行血管的占比分别为100.00%、100.00%、79.51%、86.07%、100.00%,明显高于治疗敏感组患者的83.08%、60.00%、63.08%、69.23%、80.00%,差异均有统计学意义(P<0.05)。结论乳腺超声造影在预测HER-2阳性乳腺癌曲妥珠单抗治疗敏感性中有一定价值,可指导临床治疗。 展开更多
关键词 乳腺癌 人类表皮生长因子受体2阳性 曲妥珠单抗 乳腺超声造影 化疗敏感性
下载PDF
酪氨酸激酶抑制剂治疗Her-2阳性乳腺癌脑转移疗效的单臂meta分析
6
作者 邵丽华 宋海侠 +4 位作者 祁月潇 董玉梅 郭丽云 蔡雅琴 魏世鸿 《中国医药科学》 2024年第11期124-129,共6页
目的探讨酪氨酸激酶抑制剂(TKIs)在Her-2阳性乳腺癌脑转移(BCBM)中的疗效。方法检索从建库至2022年4月11日数据库(PubMed、Cochranelibrary、Embase)中TKIs治疗Her-2阳性BCBM的临床研究,采用STATA 17.0进行meta分析。结果纳入15项研究,... 目的探讨酪氨酸激酶抑制剂(TKIs)在Her-2阳性乳腺癌脑转移(BCBM)中的疗效。方法检索从建库至2022年4月11日数据库(PubMed、Cochranelibrary、Embase)中TKIs治疗Her-2阳性BCBM的临床研究,采用STATA 17.0进行meta分析。结果纳入15项研究,其中3项关于TKIs单药治疗,12项关于联合治疗,meta分析显示TKIs单药治疗的疗效欠佳,与未使用TKIs治疗相比总生存期(OS)差异不显著(P>0.05),但TKIs联合治疗的疗效改善,与未使用TKIs治疗、未使用抗Her-2治疗或仅基于曲妥珠单抗治疗相比,OS差异有统计学意义(P<0.05);中枢神经系统(CNS)进展为TKIs单药或联合药物治疗的主要进展方式,发生率为59.0%~82.2%,而TKIs联合放疗的CNS复发率降低为22.9%。结论基于TKIs的联合治疗能够改善Her-2阳性BCBM的预后,但CNS复发率仍然很高,TKIs联合放疗能够降低CNS复发率,但相关的前瞻性临床研究较少,需更多前瞻性临床研究进一步确定最佳治疗策略。 展开更多
关键词 her-2阳性乳腺癌 脑转移 酪氨酸激酶抑制剂 META分析
下载PDF
TCbHP在老年HER-2阳性乳腺癌患者新辅助化疗中的应用效果
7
作者 王禾 方琦 王秀 《中外医学研究》 2024年第18期129-132,共4页
目的:研究TCbHP在老年HER-2阳性乳腺癌患者新辅助化疗中的应用效果。方法:选取2020年3月—2022年4月苏州大学附属第三医院收治的100例老年HER-2阳性乳腺癌患者,随机将其分为对照组(n=50)和观察组(n=50)。对照组给予THP新辅助化疗,观察... 目的:研究TCbHP在老年HER-2阳性乳腺癌患者新辅助化疗中的应用效果。方法:选取2020年3月—2022年4月苏州大学附属第三医院收治的100例老年HER-2阳性乳腺癌患者,随机将其分为对照组(n=50)和观察组(n=50)。对照组给予THP新辅助化疗,观察组给予TCbHP新辅助化疗。比较两组临床疗效、治疗前后肿瘤标志物及不良反应。结果:观察组客观缓解率高于对照组,差异有统计学意义(P<0.05)。治疗后,两组癌胚抗原与糖类抗原125水平均低于治疗前,观察组癌胚抗原与糖类抗原125水平均低于对照组,差异有统计学意义(P<0.05)。两组血小板减少、肝损伤、脱发、恶心呕吐、手足综合征发生率比较,差异无统计学意义(P>0.05)。结论:相比THP,TCbHP可进一步抑制老年HER-2阳性乳腺癌患者肿瘤标志物表达,有效控制疾病发展,不会加重化疗引起的不良反应。 展开更多
关键词 人表皮生长因子受体-2阳性 单抗 新辅助化疗 紫杉醇 乳腺癌
下载PDF
Navigating breast cancer brain metastasis:Risk factors,prognostic indicators,and treatment perspectives
8
作者 Jayalingappa Karthik Amit Sehrawat +1 位作者 Mayank Kapoor Deepak Sundriyal 《World Journal of Clinical Oncology》 2024年第5期594-598,共5页
In this editorial,we comment on the article by Chen et al.We specifically focus on the risk factors,prognostic factors,and management of brain metastasis(BM)in breast cancer(BC).BC is the second most common cancer to ... In this editorial,we comment on the article by Chen et al.We specifically focus on the risk factors,prognostic factors,and management of brain metastasis(BM)in breast cancer(BC).BC is the second most common cancer to have BM after lung cancer.Independent risk factors for BM in BC are:HER-2 positive BC,triplenegative BC,and germline BRCA mutation.Other factors associated with BM are lung metastasis,age less than 40 years,and African and American ancestry.Even though risk factors associated with BM in BC are elucidated,there is a lack of data on predictive models for BM in BC.Few studies have been made to formulate predictive models or nomograms to address this issue,where age,grade of tumor,HER-2 receptor status,and number of metastatic sites(1 vs>1)were predictive of BM in metastatic BC.However,none have been used in clinical practice.National Comprehensive Cancer Network recommends screening of BM in advanced BC only when the patient is symptomatic or suspicious of central nervous system symptoms;routine screening for BM in BC is not recommended in the guidelines.BM decreases the quality of life and will have a significant psychological impact.Further studies are required for designing validated nomograms or predictive models for BM in BC;these models can be used in the future to develop treatment approaches to prevent BM,which improves the quality of life and overall survival. 展开更多
关键词 breast cancer Brain metastasis HER2 positive metastatic breast cancer Risk factors Predictive models
下载PDF
Quantitative expression of MMP-2 and FN in high metastatic and low metastatic cell lines of breast cancer
9
作者 肖春花 《外科研究与新技术》 2005年第3期162-162,共1页
To analyze the relation of matrix metalloproteinase-2(MMP-2) and Fibronection (FN) mRNA expression with metastasis of breast cancer and elucidate the role of MMP-2 and FN in breast cancer metastasis.Methods The expres... To analyze the relation of matrix metalloproteinase-2(MMP-2) and Fibronection (FN) mRNA expression with metastasis of breast cancer and elucidate the role of MMP-2 and FN in breast cancer metastasis.Methods The expression of MMP-2 and FN mRNA in breast cancer cell lines was detected by fluorescence-quantitative RT-PCR.The expression of MMP-2 and FN protein was detected by Western blots.Results The expression of MMP-2 and FN mRNA was down-regulated in high metastatic cell lines MDA-MB-231,MDA-MB-435,but up-regulated in low metastatic cell lines MDA-453,T47D,SK-BR-3 and non-metastatic cell line MCF-7,ZR-75-30.The protein expression of MMP-2 and FN was up-regulated in high mestastic cell lines,and down-regulated in low metastatic cell lines.Conclusion The mRNA and protein expression of MMP-2 and FN was related with breast cancer metastasis.The mRNA expression of MMP-2 and FN is feed-back regulated with protein expression.6 refs,4 figs,2 tabs. 展开更多
关键词 Quantitative expression of MMP-2 and FN in high metastatic and low metastatic cell lines of breast cancer
下载PDF
三阳性乳腺癌与Her-2过表达型乳腺癌的预后分析
10
作者 张欣然 韩正祥 《徐州医科大学学报》 CAS 2024年第5期313-318,共6页
目的通过探讨三阳性乳腺癌与人表皮生长因子受体2(human epidermal growth factor receptor-2,Her-2)过表达型乳腺癌的临床病理特征及预后的差异,揭示这2种亚型的异质性,以期为这2种乳腺癌诊疗方案的选择提供数据支撑。方法收集2016年7... 目的通过探讨三阳性乳腺癌与人表皮生长因子受体2(human epidermal growth factor receptor-2,Her-2)过表达型乳腺癌的临床病理特征及预后的差异,揭示这2种亚型的异质性,以期为这2种乳腺癌诊疗方案的选择提供数据支撑。方法收集2016年7月至2022年9月在徐州医科大学附属医院诊断和收治的三阳性乳腺癌患者179例,Her-2过表达型乳腺癌患者161例,采用病例对照的方法,对其临床资料进行回顾性分析,研究其临床病理特征及预后状况。结果与Her-2过表达型乳腺癌相比,三阳性乳腺癌发病年龄更早,较常发生于绝经前的患者,TNM分期较晚,更容易侵犯脉管和神经,Ki-67(proliferating cell nucleus antigen 67,Ki67)多为高表达;三阳性乳腺癌患者的总生存期(overall survival,OS)与无进展生存期(progression-free survival,PFS)均高于Her-2过表达型。结论三阳性乳腺癌患者的预后优于Her-2过表达型,但由于其靶向治疗与内分泌治疗存在交叉作用,具有耐药性的弊端,需要进一步探究。 展开更多
关键词 三阳性乳腺癌 her-2过表达型乳腺癌 临床病理特征 预后分析
下载PDF
TCbHP新辅助化疗治疗HER-2阳性乳腺癌的临床疗效及其相关因素研究
11
作者 陈春春 唐经纬 +3 位作者 孙岩峰 张浩 乔梦祥 郭伟 《川北医学院学报》 CAS 2024年第8期1122-1126,共5页
目的:探究紫杉类+铂类(TCbHP)新辅助化疗方案治疗人表皮生长因子受体-2(HER-2)阳性乳腺癌的临床疗效,并分析其影响因素。方法:根据新辅助治疗方案不同将80例HER-2阳性乳腺癌患者分为对照组及观察组,每组各40例。对照组采用紫杉类单药(T... 目的:探究紫杉类+铂类(TCbHP)新辅助化疗方案治疗人表皮生长因子受体-2(HER-2)阳性乳腺癌的临床疗效,并分析其影响因素。方法:根据新辅助治疗方案不同将80例HER-2阳性乳腺癌患者分为对照组及观察组,每组各40例。对照组采用紫杉类单药(THP)新辅助化疗方案治疗;观察组采用TCbHP新辅助化疗方案治疗。记录并比较两组患者一般资料、病理完全缓解率及不良反应发生情况,采用Logistic回归分析影响患者病理完全缓解率的相关因素,制作受试者工作曲线(ROC),并以曲线下面积(AUC)分析各指标对患者病理完全缓解率的预测价值。结果:观察组病理完全缓解率高于对照组(P<0.05)。两组患者不良反应发生率无统计学差异(P>0.05)。Logistic分析显示,有并发症、激素受体为阴性、Ki67表达率≥30%、HER-2表达为+++及采用THP治疗均为影响患者病理完全缓解率的独立危险因素。经ROC曲线分析发现,是否有并发症、激素受体状况、Ki-67表达率、HER-2表达及治疗方式均对预测患者病理完全缓解情况具有较高敏感度及特异度,且各指标联合诊断的AUC为0.817,敏感度为0.667,特异度为0.860。结论:相较于THP治疗,HER-2阳性乳腺癌患者采用TCbHP治疗后病理完全缓解率较高,有并发症、激素受体为阴性、Ki67表达率≥30%、HER-2表达为+++及治疗方式为THP均是病理完全缓解率的影响因素,且该类指标可对病理是否完全缓解具有预测价值。 展开更多
关键词 乳腺癌 人表皮生长因子受体2阳性 新辅助化疗 病理完全缓解率 影响因素
下载PDF
曲妥珠单抗联合吡咯替尼治疗HER-2阳性乳腺癌的效果及对肿瘤标志物水平的影响
12
作者 涂兴峰 黎鹏飞 李蒙玲 《临床合理用药杂志》 2024年第29期23-26,共4页
目的观察曲妥珠单抗联合吡咯替尼治疗人表皮生长因子受体-2(HER-2)阳性乳腺癌的效果及对肿瘤标志物水平的影响。方法回顾性选取2020年6月—2022年7月龙岩市第一医院收治的HER-2阳性乳腺癌患者90例,根据治疗方式不同分为联合单抗组(n=55... 目的观察曲妥珠单抗联合吡咯替尼治疗人表皮生长因子受体-2(HER-2)阳性乳腺癌的效果及对肿瘤标志物水平的影响。方法回顾性选取2020年6月—2022年7月龙岩市第一医院收治的HER-2阳性乳腺癌患者90例,根据治疗方式不同分为联合单抗组(n=55)和吡咯替尼组(n=35)。吡咯替尼组采用吡咯替尼治疗,联合单抗组采用曲妥珠单抗联合吡咯替尼治疗,21 d为1个疗程,2组均持续治疗4个疗程。比较2组近期疗效,治疗前后血清相关指标[干扰素-γ、白介素-10(IL-10)、胸苷激酶1(TK-1)、肿瘤坏死因子-α(TNF-α)]、血清肿瘤标志物[癌胚抗原(CEA)、糖类抗原153(CA153)、糖类抗原125(CA125)]水平、生活质量评分量表(QOL)评分及不良反应。结果联合单抗组客观缓解率为60.00%,高于吡咯替尼组的37.14%(χ^(2)=4.472,P=0.034)。与治疗前比较,治疗4个疗程后,2组干扰素-γ、TK-1、TNF-α水平降低,且联合单抗组TK-1、TNF-α水平低于吡咯替尼组,但干扰素-γ水平高于吡咯替尼组(P<0.01),2组IL-10水平组内、组间比较差异均不显著(P>0.05);2组CEA、CA153、CA125水平降低,且联合单抗组低于吡咯替尼组(P<0.01);2组QOL评分升高,且联合单抗组高于吡咯替尼组(P<0.01)。联合单抗组与吡咯替尼组不良反应总发生率比较差异不显著(34.55%vs.31.43%,χ^(2)=0.094,P=0.760)。结论曲妥珠单抗联合吡咯替尼治疗HER-2阳性乳腺癌可发挥较好效果,显著降低患者血清肿瘤标志物水平,抑制炎性反应,维持免疫功能平衡,且不良反应无明显增加。 展开更多
关键词 乳腺癌 人表皮生长因子受体-2 阳性 曲妥珠单抗 吡咯替尼 近期疗效
下载PDF
复方苦参注射液联合TCbHP化疗方案治疗HER-2阳性乳腺癌疗效及安全性
13
作者 郭田田 《药品评价》 CAS 2024年第1期63-67,共5页
目的探究复方苦参注射液联合TCbHP(多西他赛+卡铂+曲妥珠单抗+帕妥珠单抗)化疗方案治疗HER-2阳性乳腺癌的疗效及安全性。方法选取2016年1月至2018年1月新乡市第二人民医院收治的102例HER-2阳性乳腺癌患者,采用随机数字表法分为对照组和... 目的探究复方苦参注射液联合TCbHP(多西他赛+卡铂+曲妥珠单抗+帕妥珠单抗)化疗方案治疗HER-2阳性乳腺癌的疗效及安全性。方法选取2016年1月至2018年1月新乡市第二人民医院收治的102例HER-2阳性乳腺癌患者,采用随机数字表法分为对照组和研究组,各51例。对照组采用TCbHP化疗方案治疗,研究组采用复方苦参注射液联合TCbHP化疗方案治疗。比较两组临床疗效、治疗前及治疗3个周期后生存质量测定量表简表(QOL-BREF)评分,中医证候积分,血清肿瘤标志物[糖类抗原153(CA153)、糖类抗原125(CA125)、糖类抗原199(CA199)、癌胚抗原(CEA)]水平,血清癌胚抗原相关细胞黏附分子1(CEACAM1),四跨膜蛋白超家族成员1(TM4SF1)水平,5年生存率。结果研究组客观缓解率(ORR)(62.75%)高于对照组(43.14%)(P<0.05)。治疗3个周期后,研究组QOL-BREF评分高于对照组(P<0.05);研究组中医证候积分均低于对照组(P<0.05);研究组血清CA153、CA125、CA199、CEA水平低于对照组(P<0.05);研究组血清CEACAM1、TM4SF1水平低于对照组(P<0.05)。治疗期间研究组血小板降低、白细胞降低、肝功能损害、腹泻发生率(13.73%、7.84%、3.92%、5.88%)低于对照组(31.37%、23.53%、17.65%、21.57%)(P<0.05)。研究组5年生存率(44.68%)高于对照组(24.49%)(P<0.05)。结论采用复方苦参注射液联合TCbHP化疗方案治疗可显著抑制HER-2阳性乳腺癌患者病情进展,缓解症状,延长生存期,提高临床疗效及生存质量。 展开更多
关键词 复方苦参注射液 TCbHP her-2阳性乳腺癌 疗效
下载PDF
黄芪多糖在Her-2阳性乳腺癌患者化疗中增效减毒的作用及其对血清Her-2-ECD、TAP和疗效的影响
14
作者 周芹芹 林芬 +1 位作者 钟小娟 袁云 《中国医学创新》 CAS 2024年第20期57-62,共6页
目的:探讨黄芪多糖在人表皮生长因子受体-2(human epidermal growth factor receptor-2,Her-2)阳性乳腺癌患者化疗中增效减毒的作用及其对血清人表皮生长因子受体-2胞外段(human epidermal growth factor receptor-2-extracellular doma... 目的:探讨黄芪多糖在人表皮生长因子受体-2(human epidermal growth factor receptor-2,Her-2)阳性乳腺癌患者化疗中增效减毒的作用及其对血清人表皮生长因子受体-2胞外段(human epidermal growth factor receptor-2-extracellular domain,Her-2-ECD)、肿瘤异常糖链糖蛋白(tumor abnormal protein,TAP)和疗效的影响。方法:选择2020年1月—2023年6月新余北湖医院收治的90例Her-2阳性乳腺癌患者作为研究对象,将患者随机分为对照组和观察组,各45例。两组均给予TCbHP(多西他赛+卡铂+曲妥珠单抗+帕妥珠单抗)方案治疗;观察组在此基础上给予注射用黄芪多糖治疗。比较两组治疗前后的中医症候积分、血清Her-2-ECD、TAP水平、免疫功能(CD4^(+)、CD8^(+))、白细胞(white blood cell,WBC)水平、乳腺癌患者的生活质量量表(functional assessment of cancer therapy-breast,FACT-B)评分、疗效及不良反应发生率。结果:治疗前,两组各项中医症候积分、Her-2-ECD、TAP、CD4^(+)、CD8^(+)、WBC、FACT-B评分比较,差异均无统计学意义(P>0.05)。治疗后,观察组各项中医症候评分、Her-2-ECD、TAP、CD8^(+)、FACT-B各项评分及不良反应发生率均低于对照组,CD4^(+)、WBC、总有效率均高于对照组,差异均有统计学意义(P<0.05)。结论:黄芪多糖能够改善Her-2阳性乳腺癌化疗患者的化疗效果,减轻化疗带来的毒性反应,提高患者的生活质量。 展开更多
关键词 黄芪多糖 人表皮生长因子受体-2阳性乳腺癌 化疗 人表皮生长因子受体-2胞外段 肿瘤异常糖链糖蛋白
下载PDF
补血养心抗癌汤辅助化疗对HER-2阳性乳腺癌患者血清PCSK9、CCL20水平的影响
15
作者 贾佳 孟林凡 于东波 《中医药临床杂志》 2024年第9期1772-1776,共5页
目的:分析人表皮生长因子受体2(Human epidermal growth factor receptor-2,HER-2)阳性乳腺癌患者经补血养心抗癌汤辅助多西他赛+卡铂化疗方案治疗前后血清前蛋白转化酶枯草溶菌素9(Recombinant Proprotein Convertase Subtilisin/Kexin... 目的:分析人表皮生长因子受体2(Human epidermal growth factor receptor-2,HER-2)阳性乳腺癌患者经补血养心抗癌汤辅助多西他赛+卡铂化疗方案治疗前后血清前蛋白转化酶枯草溶菌素9(Recombinant Proprotein Convertase Subtilisin/Kexin Type,PCSK9)、趋化因子配体20(,CCL20)水平的变化。方法:回顾性分析2021年1月—2023年1月82例HER-2阳性乳腺癌患者资料,按不同治疗方案分为对照组、观察组,各41例。对照组采用多西他赛+卡铂化疗方案治疗,观察组采用补血养心抗癌汤辅助多西他赛+卡铂化疗方案治疗,21 d为1个周期,2组均持续治疗6个周期。比较2组临床疗效、中医证候积分、HER-2表达、PCSK9、CCL20及不良反应。结果:观察组临床有效率(58.54%)高于对照组(36.59%);与对照组比较,治疗后观察组中医证候主症、次症、总积分均较低;治疗后观察组HER-2转阴率高于对照组,HER-2强阳表达率低于对照组;与治疗前比较,2组PCSK9、CCL20均降低,且观察组更为显著,差异均有统计学意义。2组恶心呕吐、脱发、心脏毒性、骨髓抑制等不良反应发生率比较,无明显差异。结论:补血养心抗癌汤辅助多西他赛+卡铂化疗方案治疗HER-2阳性乳腺癌可下调PCSK9、CCL20表达,有效控制病情、促进HER-2转阴,疗效显著,且安全性高。 展开更多
关键词 her-2阳性 乳腺癌 补血养心抗癌汤 前蛋白转化酶枯草溶菌素9 趋化因子配体20
下载PDF
Downregulation of wild-type p53 protein by HER-2/neu mediated PI3K pathway activation in human breast cancer cells: its effect on cell proliferation and implication for therapy 被引量:8
16
作者 LiZHENG JiaQiangREN HuaLI ZhaoLuKONG HongGuangZHU 《Cell Research》 SCIE CAS CSCD 2004年第6期497-506,共10页
Overexpression and activation of HER-2/neu (also known as c-erbB-2), a proto-oncogene, was found in about 30% of human breast cancers, promoting cancer growth and making cancer cells resistant to chemo- and radio-ther... Overexpression and activation of HER-2/neu (also known as c-erbB-2), a proto-oncogene, was found in about 30% of human breast cancers, promoting cancer growth and making cancer cells resistant to chemo- and radio-therapy. Wild-type p53 is crucial in regulating cell growth and apoptosis and is found to be mutated or deleted in 60-70% of human cancers. And some cancers with a wild-type p53 do not have normal p53 function, suggesting that it is implicated in a complex process regulated by many factors. In the present study, we showed that the overexpression of HER-2/neu could decrease the amount of wild-type p53 protein via activating PI3K pathway, as well as inducing MDM2 nuclear translocation in MCF7 human breast cancer cells. Blockage of PI3K pathway with its specific inhibitor LY294002 caused Gl-S phase arrest, decreased cell growth rate and increased chemo- and radio-therapeutic sensitivity in MCF7 cells expressing wild-type p53. However, it did not increase the sensitivity to adriamycin in MDA-MB-453 breast cancer cells containing mutant p53. Our study indicates that blocking PI3K pathway activation mediated by HER-2/neu overexpression may be useful in the treatment of breast tumors with HER-2/neu overexpression and wild-type p53. 展开更多
关键词 her-2/NEU PI3K breast cancer p53 MDM2
下载PDF
CORRELATION BETWEEN SERUM HER-2 ONCOPROTEIN AND PATIENTS WITH BREAST CANCER 被引量:8
17
作者 PengYuan Bing-heXu Da-tongChu 《Chinese Medical Sciences Journal》 CAS CSCD 2004年第3期212-215,共4页
To detect serum HER-2 oncoprotein levels in patients with operable and metastatic breast cancers, and to study the correlations between serum HER-2 level and lymph node status as well as other clinical parameters. Met... To detect serum HER-2 oncoprotein levels in patients with operable and metastatic breast cancers, and to study the correlations between serum HER-2 level and lymph node status as well as other clinical parameters. Methods A total of 120 women were studied consisting of 10 healthy volunteers, 31 benign breast disease, 53 operable breast cancer, and 26 metastatic breast cancer patients. The levels of serum HER-2 were measured using an enzyme-liked im-munosorbent assay (ELISA). Results The mean serum HER-2 levels were 9.6 ± 1.5 ng/mL in healthy volunteers, 11.9 ± 1.6 ng/mL in benign breast disease, 13.2 ± 4.2 ng/mL in operable breast cancer, and 30.5 ± 30.8 ng/mL in metastatic breast cancer patients. The former is much lower than the latter three (P = 0.02, 0.001, 0.03, respectively). If using 15 ng/mL as a normal baseline, elevated serum HER-2 levels were observed in none of the healthy volunteers as well as patients with benign disease, but in 18.9% (10/53) operable breast cancer patients and 61.5% (16/26) metastatic patients. In patients with operable breast cancer, there was a positive correlation between serum concentrations of HER-2 and the size of primary tumor (P < 0.05), whereas there was no correlation between serum concentration and axillary lymph node or estrogen receptor status. In patients with metastatic dise-ase, there was no correlation with site of metastases (P > 0.05). Conclusion Serum HER-2 level was strongly correlated with tumor loads and clinical stages, thus acting as a promising predictor of cancer recurrence in breast cancer patients. 展开更多
关键词 breast cancer serum her-2 ELISA
下载PDF
GENISTEIN INHIBITS EXPRESSION OF VASCULAR ENDOTHELIAL GROWTH FACTOR IN HER-2/NEU TRANSFECTED HUMAN BREAST CANCER MCF-7 CELLS 被引量:3
18
作者 朱俊东 余小平 糜漫天 《Chinese Journal of Cancer Research》 SCIE CAS CSCD 2006年第2期83-87,共5页
Objective: our previous studies have demonstrated that HER-2/neu gene expression in human breast cancer MCF-7 cells promotes angiogenesis in MCF-7 cells xenograft tumors, and genistein inhibits angiogenesis in MCF-7 ... Objective: our previous studies have demonstrated that HER-2/neu gene expression in human breast cancer MCF-7 cells promotes angiogenesis in MCF-7 cells xenograft tumors, and genistein inhibits angiogenesis in MCF-7 cells with HER-2/neu expression xenograft tumors. Here, the effects of genistein on the expression of vascular endothelial growth factor (VEGF) in MCR-7 cells with HER-2/neu expression were further studied for exploring the molecular mechanism of anti-angiogenesis in HER-2/neu-overexpressing breast cancer by genistein. Methods: HER-2/neu-overexpressing MCF-7 cells (MCF-7/HER-2) were established by transfecting HEg-2/neu gene into HER-2/neu negative expression breast cancer MCF-7 cells. Immunocytochemical staining, western blot and reverse transcription-polymerase chain reaction (RT-PCR) were adopted to measure the expression of VEGF in MCF-7/HER-2 cells treated by genistein for 24, 48 and 72h. Results: HER-2/neu expression up-regulated VEGF mRNA and protein in MCF-7 cells, genistein decreased VEGF mRNA and protein level in MCF-7/HER-2 cells in a time-dependent manner. Conclusion: These results suggest that VEGF plays an important role in HER-2/neu gene expression promoted antiogenesis in breast cancer and genistein induced down-regulation of the expression of VEGF may be one of the molecular mechanisms of its anti-angiogenesis in HER-2/neu-overexpressing breast cancer. 展开更多
关键词 GENISTEIN Vascular endothelial growth factor her-2/NEU breast cancer
下载PDF
Comparison of Fluorescence in situ Hybridization and Immunohistochemistry for Assessment of HER-2 Status in Breast Cancer Patients 被引量:3
19
作者 王琳 王晓蓓 +1 位作者 聂秀 马玲 《Journal of Huazhong University of Science and Technology(Medical Sciences)》 SCIE CAS 2009年第3期354-358,共5页
The accurate assessment ofa proto-oncogene, human epidermal growth factor receptor-2 gene (HER-2), is extremely important for the therapy and prognosis of breast cancer. Currently, immunohistochemistry (IHC) is th... The accurate assessment ofa proto-oncogene, human epidermal growth factor receptor-2 gene (HER-2), is extremely important for the therapy and prognosis of breast cancer. Currently, immunohistochemistry (IHC) is the method widely used for the detection of HER-2 protein. Fluorescence in situ hybridization (FISH) has been suggested to be a golden standard assay for HER-2 amplification. This study examined the expression and amplification of HER-2 in paraffin-embedded sections of breast cancer tissues, and compared the two methods on the measurement of HER-2 status. HER-2 gene and protein were determined in breast cancer samples from 52 Chinese women by FISH and IHC respectively. The findings indicated that the HER-2 gene amplification was found in 18 cases (34.6%) by FISH and the HER-2 protein over-expression (score 3+) in 15 cases (28.8%) by IHC. hnmunohistochemically, 28.6% of the cases scored as 2+ and 93.3% of the cases scored as 3+ were HER-2-positive by FISH. There was a significant correlation between the HER-2 gene amplification and HER-2 protein over-expression in breast cancer (P〈0.005). No correlation was noted between the HER-2 gene amplification and any of the clinicopathological parameters examined, including age, menopausal status, menarche age, tumor size, histological tumor type, histological grade, lymph node status, and the expression of ER and PR. It was concluded that the detection of HER-2 gene amplification in breast cancer by FISH is valuable and can compare with HER-2 protein detection by IHC. 展开更多
关键词 her-2 fluorescence in situ hybridization IMMUNOHISTOCHEMISTRY breast cancer
下载PDF
Axillary lymph node management in breast cancer with positive sentinel lymph node biopsy 被引量:7
20
作者 Ioannis A Voutsadakis Silvana Spadafora 《World Journal of Clinical Oncology》 CAS 2015年第1期1-6,共6页
The surgical treatment of localized breast cancer has become progressively less aggressive over the years.The management of the axillary lymph nodes has been modified by the introduction of sentinel lymph node biopsy.... The surgical treatment of localized breast cancer has become progressively less aggressive over the years.The management of the axillary lymph nodes has been modified by the introduction of sentinel lymph node biopsy. Axillary dissection can be avoided in patients with sentinel lymph node negative biopsies. Based on randomized trials data, it has been proposed that no lymph node dissection should be carried out even in certain patients with sentinel lymph node positive biopsies. This commentary discusses the basis of such recommendations and cautions against a general omission of lymph node dissection in breast cancer patients with positive sentinel lymph node biopsies. Instead, an individualized approach based on axillary tumor burden and biology of the cancer should be considered. 展开更多
关键词 Tumor sub-types Micro-metastatic NODE positive breast cancer AXILLARY LYMPH NODE DISSECTION Macro-metastatic AXILLARY recurrence
下载PDF
上一页 1 2 14 下一页 到第
使用帮助 返回顶部